QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors
A legfontosabb adatok
- Ki végzi
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- Korai 1. fázis
- Résztvevők
- 7 fő, tervezett
- Kezdés
- 2026. máj. 31.
- Várható befejezés
- 2027. máj. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- QH101 Cell Injection
- A regiszteradat frissítve
- 2026. június 18.
Ki vehet részt
The trial is looking for adults with a solid cancer that has spread to the brain, the brain or spinal cord linings (meninges), or the spinal cord. Standard treatment must have failed, or there must be no standard option. Everyone gets QH101, a donor cell therapy given into the spinal fluid.
- Életkor
- 18 years or older
- Nem
- All sexes
- A betegség stádiuma
- Spread (metastases) to the brain, meninges or spinal cord, confirmed by tissue tests. Brain lesions cannot be removed by surgery, or meningeal or spinal cord lesions cannot be operated on. Brain lesions grew after standard radiotherapy (WBRT/SRS) and repeat radiotherapy is not possible. At least one measurable lesion on contrast MRI, unless only the meninges are affected. Able to carry out daily activities (ECOG ≤2 or KPS ≥60). Expected to live at least 8 weeks.
- Korábbi kezelés
- Standard therapy must have failed or not exist. No radiation to the brain or spinal cord within 7 days before the first QH101 dose. No earlier CAR-T or other cell immunotherapy.
- Biomarker vagy leletérték
- Blood tests before the first dose: WBC ≥ 3 × 10⁹/L, lymphocytes ≥ 0.8 × 10⁹/L, Hb ≥ 90 g/L, platelets ≥ 90 × 10⁹/L, ALT and AST < 1.5×ULN, creatinine < 1.5×ULN, total bilirubin < 1.5×ULN, PT and APTT ≤ 1.25×ULN. Negative pregnancy test for women who can become pregnant.
- A részvétel fő kizáró okai
- Blood cancers such as lymphoma or leukemia that spread to the brain or spinal cord
- Spread to the brainstem or upper neck spinal cord (C1/2)
- Strong pressure inside the skull or large swelling from brain lesions
- Epilepsy that medicine does not control well
- Active infections, immune deficiency, serious heart problems, or being unable to have an MRI
A regiszter összes feltétele (25)A regiszter feltételeinek elrejtése
Ki vehet részt
- Age ≥18 years
- ECOG ≤2 or KPS ≥60
- Life expectancy ≥8 weeks as assessed by the investigator
- Pathologically and/or histologically confirmed malignant tumors with brain, meningeal, and spinal cord metastases that have failed standard therapy or lack standard treatment options may be considered for enrollment
- Intracranial metastases must meet the following characteristics:; Unresectable by craniotomy for solitary/focal (≤3 lesions)/multiple (>3 lesions) intracranial metastases; or inoperable leptomeningeal or spinal cord metastases; Inclusion Criteria Intracranial lesions that progressed after standard treatment, including whole-brain radiotherapy/stereotactic radiosurgery (WBRT/SRS), and are not suitable for repeat radiotherapy
- For brain/spinal cord parenchymal metastases, contrast-enhanced MRI must show at least one measurable lesion (according to iRANO criteria); for patients with meningeal lesions only, those deemed likely to benefit from this study by investigator judgment may also be considered for inclusion (efficacy assessed using RANO-LM criteria)
- Basic normal bone marrow reserve function and normal hepatic and renal function (laboratory tests must meet the following criteria prior to first QH101 administration):; White blood cell count (WBC) ≥ 3 × 10⁹/L; Lymphocyte count (LY) ≥ 0.8 × 10⁹/L; Hemoglobin (Hb) ≥ 90 g/L; Platelet count (PLT) ≥ 90 × 10⁹/L; Alanine aminotransferase (ALT) \& aspartate aminotransferase (AST) < 1.5×ULN; Serum creatinine (Cr) < 1.5×ULN; Total bilirubin < 1.5×ULN; PT \& APTT ≤ 1.25×ULN
- Pregnancy test must be negative for women of childbearing potential; both male and female subjects must agree to use effective contraception during treatment and for 1 year thereafter
- Ability to understand trial requirements and procedures, and willingness to participate in the clinical study as required
- Signing of the trial informed consent form
Ki nem vehet részt
- Received central nervous system-directed radiation within 7 days prior to the first infusion of QH101
- Currently receiving any other investigational treatments
- Previously received CAR-T or other cellular immunotherapies
- Patients with hematologic malignancies (such as lymphoma, leukemia, etc.) with central nervous system metastases
- Patients with primary or secondary epilepsy/epileptic syndrome that is difficult to control with medication
- Uncontrolled comorbidities, including but not limited to: ongoing or active infections, symptomatic congestive heart failure, unstable angina, arrhythmias, or psychiatric/social conditions limiting patient compliance with study requirements
- Known psychiatric disorders or substance abuse disorders that may affect compliance with trial requirements
- Patients with active infections requiring systemic treatment
- Severe cardiovascular damage: history of New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, myocardial infarction or stroke within 6 months after first dosing, or clinically significant arrhythmias requiring treatment at screening
- Allergic to immunotherapy or related cellular therapies
- Patients with metastases in the brainstem and high cervical spinal cord, including midbrain, pons, medulla oblongata, and C1/2 segments of the cervical spinal cord
- Patients with significant mass effect from intracranial lesions and signs of increased intracranial pressure (such as severe headache, projectile vomiting, papilledema, altered consciousness, or imaging showing significant edema, midline shift ≥1 cm, compression of peribrain cisterns such as suprasellar cistern, quadrigeminal cistern, interpeduncular cistern, or ambient cistern)
- Diagnosed with an immunodeficiency
- Inability to undergo magnetic resonance imaging (MRI)
- Other reasons that the investigator considers make the patient unsuitable for participation in this study
Alkalmassági kérdőív
Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.
- Életkor
- Brain metastasis vagy meningeal metastasis vagy spinal cord metastasis
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
QH101 is an allogeneic TCR-enhanced Vδ2 T cell therapy product engineered to express BTN protein-specific binding elements on the cell surface. This innovative approach harnesses the natural cytotoxic capabilities of Vδ2 T cells while augmenting their ability to recognize BTN proteins, thereby significantly improving tumor cell elimination efficiency. Notably, QH101 is designed without co-stimulatory signal domains or the CD3ζ domain, which prevents T cell exhaustion from overactivation and effectively enhances in vivo persistence.
A vizsgálat csoportja
- Patients with metastatic malignant solid tumors to the brain, meninges, and spinal cordA vizsgált kezelés
Patients with malignant solid tumors metastasizing to the brain, meninges, or spinal cord receive QH101 cell injection solution via intrathecal injection or Ommaia reservoir infusion.
Kezelés: QH101 Cell Injection
Következő lépések
Az orvosodnak
Kérdőlap az orvosnak
PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 2 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.
PDF, US Letter, 1–2 oldal. A4 méretben
A vizsgálati csapatnak
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Exploratory Clinical Study of Dose Escalation for QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors Three Dose Groups Are Established: 1×10⁷ enTCR Vδ2T Cells Per Infusion (Low Dose), 3×10⁷ enTCR Vδ2T Cells Per Infusion (Medium Dose), and 6×10⁷ enTCR Vδ2T Cells Per Infusion (High Dose). The Dose Escalation Rules Are as Follows: The First Enrolled Subject Receives Low-dose Cell Infusion. If no Dose-limiting Toxicity (DLT) Events Occur After Infusion, the Second Enrolled Subject Receives Medium-dose Infusion; the Medium and Hig
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- Kérdések a feltételekről
- Forrás: NCT07656103: ki vehet részt
- A regiszteradat frissítve
- 2026. június 18.